Rienso: new parenteral iron therapy for anaemia in CKD

Rienso (ferumoxytol) is an injectable colloidal iron-carbohydrate complex for the treatment of iron deficiency anaemia in chronic kidney disease (CKD).

Dosage of Rienso is based on body weight and pre-treatment haemoglobin levels | SCIENCE PHOTO LIBRARY
Dosage of Rienso is based on body weight and pre-treatment haemoglobin levels | SCIENCE PHOTO LIBRARY

PHARMACOLOGY

Ferumoxytol is a parenteral colloidal iron-carbohydrate complex.1 A carbohydrate shell isolates the bioactive iron to minimise its immunogenicity, which may allow administration of higher doses than other intravenous iron preparations.1,2

CLINICAL STUDIES

The safety and efficacy of intravenous ferumoxytol were assessed in three open-label studies involving 837 patients with CKD and iron-deficiency anaemia. Patients were randomised to receive either ferumoxytol (two 510mg injections 2–8 days apart) or oral iron (200mg elemental iron daily for 21 days). Patients in studies 1 and 2 were not receiving haemodialysis while those in the third study were.1

Haemoglobin increase

In the first study (n=304), ferumoxytol was associated with a significant increase in haemoglobin at day 35 (the primary efficacy endpoint) compared with oral iron (mean increase 0.82g/dL versus 0.16g/dL; (p<0.0001). In addition, more than twice as many ferumoxytol patients achieved a ≥1g/dL increase in haemoglobin at day 35 (39% versus 18.4% of placebo patients). Similar findings were reported in the other two studies.1–3

Well tolerated

Ferumoxytol was well tolerated in all three studies.1–3 In a double-blind cross-over safety study involving 750 anaemic patients with CKD stages 1–5 and 5D, ferumoxytol was well tolerated in all stages of CKD with similar rates of adverse events to placebo.4

References:

  1. Rienso Summary of Product Characteristics, June 2012
  2. Provenzano R et al. Clin J Am Soc Nephrol 2009; 4: 386-93.
  3. Spinowitz BS et al. J Am Soc Nephrol 2008; 19: 1599-1605.
  4. Singh A et al. Am J Kidney Dis 2008; 52: 907-15.

View Rienso drug record
 
Further information: Takeda

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.